Inventor
TSANG KWOK YIN
US26 patents
⚠️ This page may combine multiple inventors who share the name “TSANG KWOK YIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NITTO DENKO CORP
13 patentsUS10167253B2Jan 1, 2019
Ionizable compounds and compositions and uses thereof
NITTO DENKO CORP6 citations83
US10023597B2Jul 17, 2018
RNA interference agents for p21 gene modulation
NITTO DENKO CORP6 citations83
US9695206B2Jul 4, 2017
RNA interference agents for P21 gene modulation
NITTO DENKO CORP6 citations83
US9636411B2May 2, 2017
Large scale process for preparing poly (glutamyl-glutamate) conjugates
NITTO DENKO CORP4 citations73
US11384051B2Jul 12, 2022
Ionizable compounds and compositions and uses thereof
NITTO DENKO CORP2 citations72
US12440445B2Oct 14, 2025
Fusogenic compounds for delivery of biologically active molecules
NITTO DENKO CORP0 citations61
US12319643B2Jun 3, 2025
Ionizable compounds and compositions and uses thereof
NITTO DENKO CORP0 citations61
US11413243B2Aug 16, 2022
Fusogenic compounds for delivery of biologically active molecules
NITTO DENKO CORP1 citations61
US9839694B2Dec 12, 2017
Reduction of endotoxins from polyanionic polymer conjugates
NITTO DENKO CORP0 citations52
US9295728B2Mar 29, 2016
Co-polymer conjugates
NITTO DENKO CORP0 citations52
US10405749B2Sep 10, 2019
RNA agents for P21 gene modulation
NITTO DENKO CORP0 citations51
US10080737B2Sep 25, 2018
Polymer-based hydrotropes for hydrophobic drug delivery
NITTO DENKO CORP0 citations41
US9078926B2Jul 14, 2015
Polymer conjugates with a linker
NITTO DENKO CORP0 citations41
ALLERGAN INC
11 patentsUS7226951B2Jun 5, 2007
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
ALLERGAN INC13 citations84
US7476673B2Jan 13, 2009
Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
ALLERGAN INC20 citations82
US7468391B2Dec 23, 2008
Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
ALLERGAN INC5 citations61
US6740676B2May 25, 2004
4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
ALLERGAN INC5 citations61
US6683092B1Jan 27, 2004
[3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
ALLERGAN INC4 citations61
US7638648B2Dec 29, 2009
Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
ALLERGAN INC0 citations52
US6887896B1May 3, 2005
7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
ALLERGAN INC0 citations52
US7432388B2Oct 7, 2008
Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity
ALLERGAN INC0 citations51
US7351737B2Apr 1, 2008
4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
ALLERGAN INC0 citations51
US7253319B2Aug 7, 2007
Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity
ALLERGAN INC0 citations51
US6936636B2Aug 30, 2005
5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
ALLERGAN INC1 citations50